(Reuters) - The offer represents a 45 percent premium to Ventana's closing stock price of $51.74 on Monday on Nasdaq. Roche said it made several attempts to talk to Ventana about a deal, and it remains open to negotiations.
An acquisition of Ventana, which specializes in histopathology, or tissue-based diagnostics, will allow Roche to diversify its products and broaden its diagnostic offerings, Roche said. Ventana's technology can help researchers and doctors better determine which drugs are most appropriate for individual patients -- an emerging concept known as personalized medicine.
Read more at Reuters.com Mergers News
An acquisition of Ventana, which specializes in histopathology, or tissue-based diagnostics, will allow Roche to diversify its products and broaden its diagnostic offerings, Roche said. Ventana's technology can help researchers and doctors better determine which drugs are most appropriate for individual patients -- an emerging concept known as personalized medicine.
Read more at Reuters.com Mergers News
No comments:
Post a Comment